A phase II validation of in vivo Raman spectroscopy for bladder cancer diagnosis

A phase II validation of in vivo Raman spectroscopy for bladder cancer diagnosis - Raman Spectroscopy in Bladder Cancer Diagnosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35830

Enrollment

285

Registered

2011-08-31

Start date

2013-03-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer urothelial cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Subjects (at least 18 years old and mentally competent) that present with bladder cancer symptoms at the outpatient clinic and are scheduled for transurethral resection of tumor or biopsy (TURTB) are candidates for recrution

Exclusion criteria

Exclusion criteria: Subjects scheduled for TURBT that present with macroscopic hematuria at the time of procedure are excluded from the study as the excess of blood in urine complicates the cystoscopic guidance to sites and affects the Raman spectra.

Design outcomes

Primary

Measure	Time frame
To differentiate between benign and malignant tumor in the bladder using in vivo Raman spectra for bladder cancer diagnosis	—

Secondary

Measure	Time frame
To determine grade and stage using in vivo Raman spectra for bladder cancer diagnosis	—

Countries

Netherlands

Outcome results